193 related articles for article (PubMed ID: 10454198)
1. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors.
Fry DW
Pharmacol Ther; 1999; 82(2-3):207-18. PubMed ID: 10454198
[TBL] [Abstract][Full Text] [Related]
2. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer.
Fry DW
Anticancer Drug Des; 2000 Feb; 15(1):3-16. PubMed ID: 10888032
[TBL] [Abstract][Full Text] [Related]
3. Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases.
García-Echeverría C; Fabbro D
Mini Rev Med Chem; 2004 Mar; 4(3):273-83. PubMed ID: 15032674
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
5. Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents.
Ghosh S; Liu XP; Zheng Y; Uckun FM
Curr Cancer Drug Targets; 2001 Aug; 1(2):129-40. PubMed ID: 12188886
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor tyrosine kinase inhibitors.
Wakeling AE
Curr Opin Pharmacol; 2002 Aug; 2(4):382-7. PubMed ID: 12127870
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents.
Noonberg SB; Benz CC
Drugs; 2000 Apr; 59(4):753-67. PubMed ID: 10804033
[TBL] [Abstract][Full Text] [Related]
8. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases.
Bridges AJ
Curr Med Chem; 1999 Sep; 6(9):825-43. PubMed ID: 10495354
[TBL] [Abstract][Full Text] [Related]
9. The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics.
Sun GC; Yang X; Yu Y; Zhao DW
Anticancer Agents Med Chem; 2015; 15(7):869-80. PubMed ID: 25783965
[TBL] [Abstract][Full Text] [Related]
10. An update on epidermal growth factor receptor inhibitors.
Modi S; Seidman AD
Curr Oncol Rep; 2002 Jan; 4(1):47-55. PubMed ID: 11734113
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of protein tyrosine kinases.
Fry DW; Bridges AJ
Curr Opin Biotechnol; 1995 Dec; 6(6):662-7. PubMed ID: 8527837
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor pathway inhibitors.
Baselga J; Cortes J
Cancer Chemother Biol Response Modif; 2005; 22():205-23. PubMed ID: 16110613
[No Abstract] [Full Text] [Related]
14. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors.
Janmaat ML; Giaccone G
Oncologist; 2003; 8(6):576-86. PubMed ID: 14657536
[TBL] [Abstract][Full Text] [Related]
15. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.
Laird AD; Cherrington JM
Expert Opin Investig Drugs; 2003 Jan; 12(1):51-64. PubMed ID: 12517254
[TBL] [Abstract][Full Text] [Related]
16. The ErbB receptor family: a therapeutic target for cancer.
de Bono JS; Rowinsky EK
Trends Mol Med; 2002; 8(4 Suppl):S19-26. PubMed ID: 11927283
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
18. Anti-epidermal growth factor receptor strategies to enhance radiation action.
Lammering G
Curr Med Chem Anticancer Agents; 2003 Sep; 3(5):327-33. PubMed ID: 12871078
[TBL] [Abstract][Full Text] [Related]
19. ErbB-targeted therapeutic approaches in human cancer.
Arteaga CL
Exp Cell Res; 2003 Mar; 284(1):122-30. PubMed ID: 12648471
[TBL] [Abstract][Full Text] [Related]
20. [Targeting epidermal growth factor receptor in cancer of the breast].
Diéras V; Pierga JY; Vincent-Salomon A; Beuzeboc P; Pouillart P; de Cremoux P
Bull Cancer; 2003 Nov; 90 Spec No():S257-62. PubMed ID: 14763149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
